U.S. health regulators have placed a ban on imported drugs from a factory operated by India's largest pharmaceutical company, Ranbaxy Laboratories, due to manufacturing and quality control problems.
The import alert, issued Friday by the Food and Drug Administration, effectively stops imports of 11 drugs from Ranbaxy's Mohali factory in Punjab province. The agency said Monday its inspectors uncovered multiple violations at the factory last year, including failure to investigate manufacturing problems and failure to follow quality-control standards.
"We want American consumers to be confident that the drugs they are taking are of the highest quality, and the FDA will continue to work to prevent potentially unsafe products from entering the country," said Howard Sklamberg, director of the FDA's office of compliance, in a statement.
Ranbaxy Laboratories Ltd. stock price fell by 30.3 percent to $5.10 by the close of trading on the Bombay Stock Exchange.
Ranbaxy had no immediate comment on Monday.